Director

Mr. Oakes joined our board of directors in April 2020.  He currently serves as Corporate Vice President – Global integration Lead for Otezla at Amgen where he is overseeing the integration and continued success of the $2B brand and positioning it for sustained growth.  Prior to Amgen, Mr. Oakes was Corporate Vice President and US General Manager at Celgene.  Mr. Oakes also served as the Global Commercial Integration Lead at Celgene where he helped steer the $74B acquisition by Bristol-Myers Squibb and the $13.4B divestiture of Otezla.  Prior to Celgene, Mr. Oakes held several positions at Novartis, most recently as Head of Sandoz Biopharmaceuticals, North America.  He began his career at Schering-Plough (Merck) where he held executive roles both in the US and Europe.  He holds a bachelor’s degree in Marketing and Business Administration from Edinboro University and a M.B.A. from Clemson University.  He currently sits on the Board of BioNJ and served on various Executive Committees at Celgene, Novartis, and Schering-Plough (Merck).